ATNF - 180 Life Sciences Corp.
NASDAQ
->
Healthcare
->
Biotechnology
Palo Alto,
United States
Type: Equity
ATNF price evolution
ATNF
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Jan 2023 | 30 Sep 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2.01 | $2.65 | $6.97 | $3.59 |
| Short term investments | ||||
| Net receivables | $0.09 | $0.36 | $0.62 | $0.67 |
| Inventory | ||||
| Total current assets | $2.93 | $4.2 | $8.93 | $6.51 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | $1.67 | $1.66 | $1.66 | $15.53 |
| Total noncurrent assets | $10.73 | $10.73 | $10.72 | $27.82 |
| Total investments | ||||
| Total assets | $13.67 | $14.92 | $19.65 | $34.34 |
| Current liabilities | ||||
| Accounts payable | $0.89 | $1.21 | $1.8 | $1.02 |
| Deferred revenue | ||||
| Short long term debt | $0.59 | $0.84 | $1.31 | $0.41 |
| Total current liabilities | $4.27 | $5.12 | $5.66 | $4.72 |
| Long term debt | $0.03 | $0.03 | $0.03 | $0.03 |
| Total noncurrent liabilities | $2.68 | $2.66 | $2.65 | $3.54 |
| Total debt | $0.61 | $0.87 | $1.34 | $0.44 |
| Total liabilities | $6.95 | $7.78 | $8.31 | $8.26 |
| Shareholders' equity | ||||
| Retained earnings | -$115.85 | -$112.17 | -$107.41 | -$85.67 |
| Other shareholder equity | -$2.9 | -$2.88 | -$2.89 | -$3.69 |
| Total shareholder equity | $6.72 | $7.14 | $11.34 | $26.08 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $6.97 | $8.22 | $2.11 | $0.55 |
| Short term investments | ||||
| Net receivables | $0.62 | $0.69 | $0.3 | $0.07 |
| Inventory | ||||
| Total current assets | $8.93 | $11.2 | $4.01 | $0.62 |
| Long term investments | $11.88 | |||
| Property, plant & equipment | $0.05 | |||
| Goodwill & intangible assets | $1.66 | $38.94 | $38.95 | |
| Total noncurrent assets | $10.72 | $51.51 | $51.52 | $11.88 |
| Total investments | $11.88 | |||
| Total assets | $19.65 | $62.71 | $55.53 | $12.5 |
| Current liabilities | ||||
| Accounts payable | $1.8 | $0.59 | $8.74 | $1.06 |
| Deferred revenue | ||||
| Short long term debt | $1.31 | $1.91 | $3.67 | $2.07 |
| Total current liabilities | $5.66 | $19.7 | $21.42 | $3.13 |
| Long term debt | $0.03 | $0.05 | $0.11 | |
| Total noncurrent liabilities | $2.65 | $3.69 | $3.83 | $4.03 |
| Total debt | $1.34 | $1.96 | $3.78 | $2.07 |
| Total liabilities | $8.31 | $23.39 | $25.25 | $7.15 |
| Shareholders' equity | ||||
| Retained earnings | -$107.41 | -$68.68 | -$48.36 | $1.07 |
| Other shareholder equity | -$2.89 | $0.82 | $0.64 | $0.15 |
| Total shareholder equity | $11.34 | $39.32 | $30.29 | $5 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $0.92 | $0.79 | $0.59 | $0.64 |
| Selling, general & administrative | $2.76 | $4.01 | $5.05 | $3.42 |
| Total operating expenses | $3.68 | $4.8 | $5.64 | $4.06 |
| Operating income | -$3.68 | -$4.8 | -$5.64 | -$4.06 |
| Income from continuing operations | ||||
| EBIT | -$3.67 | -$4.75 | -$22.68 | -$21.48 |
| Income tax expense | -$0.94 | |||
| Interest expense | $0.01 | $0.01 | $0.01 | $0.01 |
| Net income | ||||
| Net income | -$3.68 | -$4.76 | -$21.74 | -$21.49 |
| Income (for common shares) | -$3.68 | -$4.76 | -$21.74 | -$21.49 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $2.43 | $3.95 | $2.29 | |
| Selling, general & administrative | $15.47 | $11.69 | $3.36 | $1.21 |
| Total operating expenses | $17.9 | $15.64 | $5.65 | $1.21 |
| Operating income | -$17.9 | -$15.64 | -$5.65 | -$1.21 |
| Income from continuing operations | ||||
| EBIT | -$39.64 | -$20.16 | -$9.82 | $0.17 |
| Income tax expense | -$0.94 | -$0.02 | -$0.02 | $0.26 |
| Interest expense | $0.03 | $0.19 | $1.09 | |
| Net income | ||||
| Net income | -$38.73 | -$20.32 | -$10.88 | -$0.09 |
| Income (for common shares) | -$38.73 | -$20.32 | -$12.01 | -$0.09 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Net income | -$3.68 | -$4.76 | -$21.74 | -$21.49 |
| Operating activities | ||||
| Depreciation | $0.03 | $0.02 | $0.04 | $0.01 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.55 | $0.56 | $0.63 | $0.61 |
| Total cash flows from operations | -$3.12 | -$3.87 | -$2.93 | -$3.6 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.72 | $5.51 | $5.97 | |
| Net borrowings | -$0.26 | -$0.47 | $0.88 | -$0.48 |
| Total cash flows from financing | $2.46 | -$0.47 | $6.4 | $5.49 |
| Effect of exchange rate | $0.02 | $0.02 | -$0.09 | $0.07 |
| Change in cash and equivalents | -$0.64 | -$4.32 | $3.38 | $1.96 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$38.73 | -$20.32 | -$10.88 | -$0.09 |
| Operating activities | ||||
| Depreciation | $0.11 | $0.11 | $0.13 | |
| Business acquisitions & disposals | $3.01 | |||
| Stock-based compensation | $2.63 | $2.85 | $1.12 | |
| Total cash flows from operations | -$12.13 | -$19.37 | -$3.87 | -$1.45 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | $11.48 | $108.24 | ||
| Total cash flows from investing | $14.49 | $108.24 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $11.48 | $24.61 | -$8.93 | -$108.43 |
| Net borrowings | -$0.61 | $0.8 | $0.2 | $1.08 |
| Total cash flows from financing | $10.87 | $25.41 | -$8.73 | -$106.51 |
| Effect of exchange rate | -$0 | $0.08 | $0.14 | |
| Change in cash and equivalents | -$1.25 | $6.12 | $2.03 | $0.28 |
News
Fundamentals
| Market cap | $3.26M |
|---|---|
| Enterprise value | $1.87M |
| Shares outstanding | 5.32M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$52.48M |
| EBIT | -$52.58M |
| Net Income | -$51.67M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.06 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | -0.04 |
| EV/EBIT | -0.04 |
| P/S ratio | N/A |
| P/B ratio | 0.34 |
| Book/Share | 1.81 |
| Cash/Share | 0.38 |
| EPS | -$9.72 |
|---|---|
| ROA | -250.30% |
| ROE | -403.09% |
| Debt/Equity | 0.73 |
|---|---|
| Net debt/EBITDA | -0.09 |
| Current ratio | 0.69 |
| Quick ratio | 0.69 |